Home > Browse Research > Life Sciences > Pharmaceuticals > Diseases & Conditions > Hypertension

Hypertension: market research reports

Hypertension is an intermittent or persistent elevation of the blood pressure. It is widely believed to be one of the most important risk factors for death from stroke, congestive heart failure, and coronary heart disease (CHD) and coupled with its high and rising prevalence, is thus considered a major health threat. This is significant, since, according to the CDC, heart disease and stroke are the number one and three causes of death in the United States, accounting for more than 40% of all deaths.

Although these largely preventable conditions are more common among people aged 65 and older, the number of sudden deaths from heart disease among people aged 15 to 34 has increased. This increase is partially attributable to a more sedentary lifestyle which is causing Americans’ waistlines to expand. Studies have shown that as weight goes up, so does the incidence of hypertension. Just 14.9% of normal weight men and 15.2% of normal weight women have hypertension, this rises to 41.9% for obese men and 37.8% of obese women.

Hypertension is largely treatable through lifestyle modifications. Although in some sufferers, the disease is linked to genetics and other factors beyond the patient’s control, changes in diet, exercise and/or smoking can significantly reduce disease severity for many people. There are also numerous classes of drugs available to lower blood pressure, the most common of which are diuretics, beta-blockers, calcium-channel blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and alpha one antagonists.

Hypertension market research reports and industry analysis

Hypertension Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension ... \| read more...	$2,000.00
Hypertension – Pipeline Review, H1 2013 3/18/2013 \| published by: Global Markets Direct ... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. Hypertension - Pipeline Review, Half Year is built using data and information ... \| read more...	$2,000.00
Ocular Hypertension – Pipeline Review, H1 2013 3/18/2013 \| published by: Global Markets Direct ... Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. Ocular Hypertension - Pipeline Review, Half Year is ... \| read more...	$2,000.00
Idiopathic (Essential) Hypertension – Pipeline Review, H1 2013 2/28/2013 \| published by: Global Markets Direct ... development for Idiopathic (Essential) Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension. Idiopathic (Essential) Hypertension - ... \| read more...	$2,000.00
Pulmonary Hypertension – Pipeline Review, H1 2013 2/28/2013 \| published by: Global Markets Direct ... Pulmonary Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension. Pulmonary Hypertension - Pipeline Review, Half Year is ... \| read more...	$2,000.00
Hypotension Global Clinical Trials Review, H1, 2013 2/25/2013 \| published by: GlobalData ... to the clinical trials on Hypotension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ... \| read more...	$2,500.00
Ocular Hypertension Global Clinical Trials Review, H1, 2013 2/25/2013 \| published by: GlobalData ... and data relating to the clinical trials on Ocular Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ... \| read more...	$2,500.00
Portal Hypertension Global Clinical Trials Review, H1, 2013 1/25/2013 \| published by: GlobalData ... and data relating to the clinical trials on Portal Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers ... \| read more...	$2,500.00
Portal Hypertension – Pipeline Review, H2 2012 11/28/2012 \| published by: Global Markets Direct ... Portal Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Portal Hypertension. Portal Hypertension - Pipeline Review, Half Year is ... \| read more...	$2,000.00
Health and Wellness Devices 11/1/2012 \| published by: Kline & Company, Inc. ... act as preventive measures. Some key health and wellness devices included in this study are blood glucose monitors, blood pressure monitors, heart rate monitors, pedometers, fitness monitors, digital thermometers, teeth whitening devices, and hair growth ... \| read more...	$4,500.00
Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2012 10/31/2012 \| published by: GlobalData ... provides elemental information and data relating to the clinical trials on Pulmonary Arterial Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ... \| read more...	$2,500.00
Non-Invasive Blood Pressure Monitors Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 10/18/2012 \| published by: GlobalData ... 2018” provides key market data on the Non-Invasive Blood Pressure Monitors market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data for each segment and sub-segment within three ... \| read more...	$2,500.00
Pulmonary Arterial Hypertension 9/26/2012 \| published by: Decision Resources ... therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets under study, the PAH therapy market is a billion-dollar market and is expected to increase over the 2011-2021 forecast period. ... \| read more...	$15,000.00
China Hypertension Prescription Drug Sales Data 2007-2011 9/1/2012 \| published by: Draco Healthcare Consulting LLC ... and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, ... \| read more...	$8,000.00
Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2012 7/24/2012 \| published by: GlobalData ... provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ... \| read more...	$2,500.00
Pulmonary Arterial Hypertension (PAH) Therapeutics 7/1/2012 \| published by: Global Industry Analysts ... market for PAH Therapeutics is further analyzed by the following countries/regions - France, Germany, Italy, UK, Spain, and Rest of Europe. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a ... \| read more...	$4,450.00
Research Report on China's Antihypertensive Medicine Market, 2012 6/15/2012 \| published by: China Research and Intelligence Co., Ltd. ... death of various diseases, death toll of cardiovascular disease which is represented by hypertension increases from 28.8% of the total mortality toll in 1997 to 36.0% in 2002. Hypertension is a serious danger to human ... \| read more...	$2,800.00
Hypotension Global Clinical Trials Review, H1, 2012 5/21/2012 \| published by: GlobalData ... to the clinical trials on Hypotension . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ... \| read more...	$1,000.00
Ocular Hypertension Global Clinical Trials Review, H1, 2012 5/21/2012 \| published by: GlobalData ... and data relating to the clinical trials on Ocular Hypertension . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ... \| read more...	$1,000.00
Orthostatic Hypotension Global Clinical Trials Review, H1, 2012 5/21/2012 \| published by: GlobalData ... and data relating to the clinical trials on Orthostatic Hypotension . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ... \| read more...	$1,000.00
Epidemiology: Stroke – Aging global population leads to more incident cases of stroke 5/17/2012 \| published by: Datamonitor ... the age of 40 in each of the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) over the next 10 years. Introduction Gain insight into market potential, including a robust ... \| read more...	$3,800.00
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 4/19/2012 \| published by: Global Markets Direct ... the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. 'Pulmonary Arterial ... \| read more...	$500.00
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 3/31/2012 \| published by: GlobalData ... Analysis to 2020”, an essential and comprehensive source of information and analysis on the global Pulmonary Arterial Hypertension (PAH) therapeutics market. The report identifies and analyzes the key trends shaping and driving the global PAH ... \| read more...	$6,995.00
Treatment Algorithms: Hypertension – Multiclass combinations are common but preferences differ by market 3/27/2012 \| published by: Datamonitor ... combinations to treat hypertension, reflecting individual patient responses and comorbidities, as well as market pricing pressures. Features and benefits Follow patient segmentation and treatment pathways for hypertension across the seven major markets. Gain insight into ... \| read more...	$7,600.00

< prev 1 2 3 4 next >